{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.chat_models import init_chat_model\n",
    "from langchain_core.messages import HumanMessage\n",
    "from langchain_core.messages import SystemMessage, HumanMessage, AIMessage\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.prompts import ChatPromptTemplate, MessagesPlaceholder\n",
    "from langchain_core.messages import HumanMessage, AIMessage, BaseMessage\n",
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain.output_parsers import StructuredOutputParser, ResponseSchema\n",
    "from typing import Optional, List, Union\n",
    "from pydantic import BaseModel, Field, field_validator\n",
    "from typing import List, Optional\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "from langchain_core.output_parsers import PydanticOutputParser\n",
    "import json\n",
    "import os\n",
    "import re\n",
    "import glob\n",
    "import json\n",
    "from json import JSONEncoder\n",
    "import requests, urllib.parse\n",
    "from langchain_core.tools import tool\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Pick via provider:model string → works across providers\n",
    "llm = init_chat_model(model=\"gemini-2.5-flash\",\n",
    "                      model_provider=\"google_genai\",\n",
    "                      temperature=0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "#global_path  = \"/Users/ilboukil/Library/CloudStorage/OneDrive-SIBSwissInstituteofBioinformatics/Trainings-cb-402/ML_summer_school_code/\"\n",
    "global_path  = \"/Users/SJp/Documents/project_local/VIB-LLM-SS/ml-summerschool-2025/topic-1_data-integration-and-llms/project/results/\"\n",
    "\n",
    "patient_id = \"MM082\"\n",
    "# Path to your JSON file (e.g., patient PKG or classification output)\n",
    "json_path = f\"{global_path}/{patient_id}.json\"\n",
    "\n",
    "with open(json_path, \"r\") as f:\n",
    "    patient_json = json.load(f)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "class GNN_prediction_report(BaseModel):\n",
    "    patient_ID: Optional[Union[str, int]]  # \"555-1234\", 5551234, or None\n",
    "    disease_type: str = Field(description=\"e.g., Melanoma\")\n",
    "    recomended_drug_name: str = Field(description = \"e.g., Pembrolizumab\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "from json import JSONEncoder\n",
    "class MyEncoder(JSONEncoder):\n",
    "    def default(self, o):\n",
    "        return o.__dict__\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "@tool\n",
    "def get_openfda_label(ingredient):\n",
    "    \"\"\"\n",
    "    Fetches drug purpose, indications, usages, adverse reactions, warning, and dosage and administration information from the FDA API.\n",
    "\n",
    "    Args:\n",
    "        drug_name (str): The name of the drug (e.g., \"aspirin\").\n",
    "\n",
    "    Returns:\n",
    "        dict: The  response drug purpose, indications, usages, adverse reactions, warning, and dosage and administration information\n",
    "    \"\"\"\n",
    "    # Standardize ingredient name\n",
    "    ingredient = urllib.parse.quote(ingredient)\n",
    "    print(ingredient)\n",
    "    base = \"https://api.fda.gov/drug/label.json\"\n",
    "    q = f'openfda.substance_name:\"{ingredient}\"'\n",
    "    r = requests.get(base, params={\"search\": q, \"limit\": 1})\n",
    "    r.raise_for_status()\n",
    "    res = r.json().get(\"results\", [])\n",
    "    if not res:\n",
    "        q2 = f'openfda.brand_name:\"{ingredient}\"'\n",
    "        r = requests.get(base, params={\"search\": q2, \"limit\": 1})\n",
    "        r.raise_for_status()\n",
    "        res = r.json().get(\"results\", [])\n",
    "        if not res:\n",
    "            return None\n",
    "    return res[0]\n",
    "\n",
    "# item = get_openfda_label(\"ibuprofen\")\n",
    "\n",
    "# if item:\n",
    "#     for key in (\"purpose\",\"indications_and_usage\", \"adverse_reactions\", \"warnings\", \"dosage_and_administration\"):\n",
    "#         if key in item:\n",
    "#             print(f\"\\n=== {key} ===\\n{item[key][0][:800]}\")\n",
    "# else:\n",
    "#     print(\"Cannot find record on openFDA for that name.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "# bioassistant.py\n",
    "\n",
    "import json\n",
    "from typing import List, Dict\n",
    "from collections import defaultdict\n",
    "\n",
    "from gseapy import enrichr\n",
    "from langchain.chat_models import init_chat_model\n",
    "from langchain_core.prompts import ChatPromptTemplate\n",
    "from langchain_core.tools import tool\n",
    "\n",
    "\n",
    "# -------------------------------\n",
    "# Tool: Enrichment\n",
    "# -------------------------------\n",
    "@tool\n",
    "def enrichr_query(gene_list: List[str]):\n",
    "    \"\"\"Run enrichment analysis on a list of genes using gseapy (GO Biological Process).\"\"\"\n",
    "    enr = enrichr(\n",
    "        gene_list=gene_list,\n",
    "        gene_sets='GO_Biological_Process_2021',\n",
    "        organism='Human',\n",
    "        outdir=None,\n",
    "        cutoff=0.05\n",
    "    )\n",
    "    return enr.results  # DataFrame\n",
    "\n",
    "\n",
    "# -------------------------------\n",
    "# LLM setup\n",
    "# -------------------------------\n",
    "def get_llm_with_tools(model: str = \"gemini-2.5-flash\", provider: str = \"google_genai\"):\n",
    "    \"\"\"Initialize the chat model and bind the enrichment tool.\"\"\"\n",
    "    llm = init_chat_model(model=model, model_provider=provider, temperature=0.2)\n",
    "    return llm.bind_tools([enrichr_query])\n",
    "\n",
    "\n",
    "def get_prompt_chain(llm_with_tools):\n",
    "    \"\"\"Return a chain with system+human prompt bound to the LLM with tools.\"\"\"\n",
    "    prompt = ChatPromptTemplate.from_messages([\n",
    "        (\"system\", \"You are a helpful bioinformatics assistant. Use tools when needed.\"),\n",
    "        (\"human\", \"{question}\")\n",
    "    ])\n",
    "    return prompt | llm_with_tools\n",
    "\n",
    "\n",
    "# -------------------------------\n",
    "# SHAP → Gene Sets → Enrichment → Summarization\n",
    "# -------------------------------\n",
    "def analyze_patient(patient_json: Dict, patient_id: str, chain):\n",
    "    \"\"\"\n",
    "    Collect SHAP features per predicted class, run enrichment, and ask LLM to summarize.\n",
    "    \n",
    "    Parameters\n",
    "    ----------\n",
    "    patient_json : dict\n",
    "        JSON object with structure { patient_id: { \"Drugs\": {...}} }\n",
    "    patient_id : str\n",
    "        Patient ID key in patient_json\n",
    "    chain : LangChain runnable (prompt | llm_with_tools)\n",
    "    \n",
    "    Returns\n",
    "    -------\n",
    "    results_by_class : dict\n",
    "        { predicted_class: { \"positive\": enrichment_df, \"negative\": enrichment_df } }\n",
    "    \"\"\"\n",
    "    drug_keys = list(patient_json[patient_id][\"Drugs\"].keys())\n",
    "    class_features = defaultdict(lambda: {\"positive\": [], \"negative\": []})\n",
    "\n",
    "    # Step 1: Collect SHAP features by predicted class\n",
    "    for drug in drug_keys:\n",
    "        predicted_class = patient_json[patient_id][\"Drugs\"][drug][\"Predicted_Class\"]\n",
    "        pos_features = patient_json[patient_id][\"Drugs\"][drug]['SHAP']['Top_Positive']\n",
    "        neg_features = patient_json[patient_id][\"Drugs\"][drug]['SHAP']['Top_Negative']\n",
    "\n",
    "        class_features[predicted_class][\"positive\"].extend(\n",
    "            [item[\"Feature\"].split(\"_\", 1)[1] if \"_\" in item[\"Feature\"] else item[\"Feature\"]\n",
    "             for item in pos_features]\n",
    "        )\n",
    "        class_features[predicted_class][\"negative\"].extend(\n",
    "            [item[\"Feature\"].split(\"_\", 1)[1] if \"_\" in item[\"Feature\"] else item[\"Feature\"]\n",
    "             for item in neg_features]\n",
    "        )\n",
    "\n",
    "    # Step 2: Run enrichment\n",
    "    results_by_class = {}\n",
    "    for cls, feats in class_features.items():\n",
    "        results_by_class[cls] = {}\n",
    "        results_by_class[cls][\"positive\"] = (\n",
    "            enrichr_query({\"gene_list\": list(set(feats[\"positive\"]))}) if feats[\"positive\"] else None\n",
    "        )\n",
    "        results_by_class[cls][\"negative\"] = (\n",
    "            enrichr_query({\"gene_list\": list(set(feats[\"negative\"]))}) if feats[\"negative\"] else None\n",
    "        )\n",
    "\n",
    "    # Step 3: Summarize with LLM\n",
    "    summaries = {}\n",
    "    for cls, res in results_by_class.items():\n",
    "        question = f\"Predicted class: {cls}\\nSummarize functional biology or pathways of SHAP features.\\n\"\n",
    "\n",
    "        if res[\"positive\"] is not None and not res[\"positive\"].empty:\n",
    "            question += f\"\\nPositive SHAP features (supporting {cls}):\\n{res['positive'].head(10).to_string(index=False)}\\n\"\n",
    "        if res[\"negative\"] is not None and not res[\"negative\"].empty:\n",
    "            question += f\"\\nNegative SHAP features (against {cls}):\\n{res['negative'].head(10).to_string(index=False)}\\n\"\n",
    "\n",
    "        ai_msg = chain.invoke({\"question\": question})\n",
    "        summaries[cls] = ai_msg.content\n",
    "\n",
    "    return results_by_class, summaries\n",
    "\n",
    "\n",
    "# bioassistant.py (add at the bottom)\n",
    "\n",
    "import pandas as pd\n",
    "def save_patient_summary_html(patient_id: str,\n",
    "                              results_by_class: dict,\n",
    "                              summaries: dict,\n",
    "                              out_path: str = None):\n",
    "    \"\"\"\n",
    "    Save the enrichment results + LLM summaries into an HTML report.\n",
    "    \n",
    "    Parameters\n",
    "    ----------\n",
    "    patient_id : str\n",
    "        Patient identifier\n",
    "    results_by_class : dict\n",
    "        Output from analyze_patient (enrichment results)\n",
    "    summaries : dict\n",
    "        Output from analyze_patient (LLM summaries)\n",
    "    out_path : str\n",
    "        File path for the HTML file (default = f\"{patient_id}_summary.html\")\n",
    "    \"\"\"\n",
    "    if out_path is None:\n",
    "        out_path = f\"{patient_id}_summary.html\"\n",
    "\n",
    "    html_parts = [f\"<h1>Patient {patient_id} – Pathway Analysis Report</h1>\"]\n",
    "\n",
    "    for cls, summary in summaries.items():\n",
    "        html_parts.append(f\"<h2>Predicted Class: {cls}</h2>\")\n",
    "        html_parts.append(f\"<p><strong>LLM Summary:</strong><br>{summary}</p>\")\n",
    "\n",
    "        # Insert enrichment tables\n",
    "        for direction in [\"positive\", \"negative\"]:\n",
    "            df = results_by_class[cls].get(direction)\n",
    "            if df is not None and not df.empty:\n",
    "                html_parts.append(f\"<h3>{direction.title()} SHAP Features Enrichment</h3>\")\n",
    "                html_parts.append(df.head(15).to_html(index=False, escape=False))\n",
    "    \n",
    "    html = \"\\n\".join(html_parts)\n",
    "    with open(out_path, \"w\") as f:\n",
    "        f.write(html)\n",
    "    print(f\"✅ HTML report saved to {out_path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"\"\"You are a biomedical-AI assistant that interprets predictions from a AI-powered predictive model for clinicians.\n",
    "You are given a JSON with some information regarding the patient and 2 drugs. In the JSON, you are given:\n",
    "- Patient ID\n",
    "- Disease type\n",
    "- For each drug, you will be given:\n",
    "    - The drug name\n",
    "    - The predicted class. This class can be one of three options: \n",
    "        - No effect if the drug is predicted as having no effect on treating the patient disease\n",
    "        - Positive response if the drug is predicted as having a positive effect on treating the patient disease\n",
    "        - Adverse effects if the drug is predicted as having a negative effect on the patient disease\n",
    "    - Each predicted class has an associated probability\n",
    "    - Each predicted class has associated features, that are responsible for the prediction. To reflect the importance of these features on the prediction we have the SHAP values. We have the top positive SHAP values and the top negative SHAP values.\n",
    "\n",
    "Taking into account this JSON and the information explained above, I want you as a smart biomedical-AI assistant to pick the best of the two drugs. I don't want you to talk about the accuracy of the predicition for more than one sentence.\n",
    "Once you have  picked the best drug for my patient, I want you to write a small report on the chosen drug, please include both positive an negative points about the drug, make it as straigthforward as possible (a maximum of 10 bullet points in total), and targeted towards clinicians.\n",
    "After that, please write a short paragraph about the features involved in the decision making process, and look in the litterature for information about the relationship between these features and the disease the patient has.\"\"\"),\n",
    "    (\"human\", \"{JSON_input}\")\n",
    "])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "chain = prompt | llm | StrOutputParser()\n",
    "response = chain.invoke({\"JSON_input\": patient_json})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"For patient MM082, diagnosed with Multiple Myeloma, the AI-powered predictive model recommends the **Dexamethasone+Bortezomib+Pomalidomide (Proteasome Inhibitor regime)**. This drug combination is predicted to elicit a positive response with a probability of 88.6%, making it the most promising option compared to the other drugs which were predicted to have no effect.\\n\\n---\\n\\n### Clinical Report: Dexamethasone+Bortezomib+Pomalidomide (Proteasome Inhibitor regime) for Patient MM082\\n\\n*   **Drug Recommendation:** Dexamethasone+Bortezomib+Pomalidomide (Proteasome Inhibitor regime) is the recommended treatment for patient MM082.\\n*   **Predicted Efficacy:** The model predicts a positive therapeutic response for Multiple Myeloma in this patient.\\n*   **Confidence Level:** This positive effect is predicted with a high probability of 88.6%.\\n*   **Key Positive Indicator: Prot_YY1:** Elevated levels of the transcription factor YY1 are a strong positive indicator, significantly contributing to the predicted favorable outcome.\\n*   **Positive Indicators: Prot_RHOT2 & Prot_AFTPH:** Increased expression of RHOT2 and AFTPH also contribute substantially to the predicted positive response.\\n*   **Additional Positive Indicators:** Proteins such as EIF4E2, ALOX5AP, and TPP2 further support the prediction of a positive effect.\\n*   **Potential Negative Influence: Prot_MYO1C:** High expression of Myosin IC (MYO1C) is identified as a factor that could potentially mitigate the overall positive effect.\\n*   **Potential Negative Influence: Prot_TAP2 & Prot_DHODH:** Elevated levels of TAP2 and DHODH also show a negative influence on the predicted response.\\n*   **Clinical Consideration:** The presence of these negatively influencing features suggests potential underlying biological characteristics or resistance mechanisms that may warrant close monitoring or further investigation to optimize treatment.\\n\\n---\\n\\n### Features Involved in Decision Making\\n\\nThe AI model's prediction for Dexamethasone+Bortezomib+Pomalidomide is driven by a specific profile of protein expression in patient MM082. Key positive contributors to the predicted efficacy include **Prot_YY1**, **Prot_RHOT2**, **Prot_AFTPH**, **Prot_EIF4E2**, **Prot_ALOX5AP**, and **Prot_TPP2**. In Multiple Myeloma, the transcription factor YY1 is known to play a complex role, often implicated in cell proliferation, survival, and drug resistance, with its specific context here suggesting a favorable interaction with the treatment. EIF4E2, involved in translation initiation, and ALOX5AP, linked to inflammatory pathways, represent cellular processes frequently dysregulated in MM. TPP2, a protease, could be particularly relevant given the proteasome inhibitor (Bortezomib) component of the regimen. Conversely, features like **Prot_MYO1C**, **Prot_TAP2**, and **Prot_DHODH** negatively influence the prediction. MYO1C, involved in cell motility, might indicate a more aggressive or migratory phenotype. TAP2, crucial for MHC class I antigen presentation, can be downregulated in MM to facilitate immune evasion, and its negative contribution here might suggest a compromised immune response. DHODH, a key enzyme in pyrimidine synthesis, could point to a metabolic reliance that might not be fully addressed by the current drug combination, potentially indicating a resistance pathway. Understanding these patient-specific protein profiles can offer insights into the biological underpinnings of treatment response in Multiple Myeloma.\""
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"\"\"You are a biomedical-AI assistant that interprets predictions from a AI-powered predictive model for clinicians.\n",
    "You are given a JSON with some information regarding the patient and 2 drugs. In the JSON, you are given:\n",
    "- Patient ID\n",
    "- Disease type\n",
    "- For each drug, you will be given:\n",
    "    - The drug name\n",
    "    - The predicted class. This class can be one of three options: \n",
    "        - No effect if the drug is predicted as having no effect on treating the patient disease\n",
    "        - Positive response if the drug is predicted as having a positive effect on treating the patient disease\n",
    "        - Adverse effects if the drug is predicted as having a negative effect on the patient disease\n",
    "    - Each predicted class has an associated probability\n",
    "    - Each predicted class has associated features, that are responsible for the prediction. To reflect the importance of these features on the prediction we have the SHAP values. We have the top positive SHAP values and the top negative SHAP values.\n",
    "\n",
    "Taking into account this JSON and the information explained above, I want you as a smart biomedical-AI assistant to pick the best of the two drugs. I don't want you to talk about the accuracy of the predicition for more than one sentence.\"\"\" ), (\"human\", \"{JSON_input}\")\n",
    "])\n",
    "\n",
    "chain = prompt | llm | StrOutputParser()\n",
    "response = chain.invoke({\"JSON_input\": patient_json})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [],
   "source": [
    "parser = PydanticOutputParser(pydantic_object=GNN_prediction_report)\n",
    "format_instructions = parser.get_format_instructions()\n",
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"Extract per schema:\\n{format_instructions}\"),\n",
    "    (\"human\", \"{text}\"),\n",
    "]).partial(format_instructions=format_instructions)\n",
    "\n",
    "parsing_llm = prompt | llm | parser\n",
    "\n",
    "# if `drug_text` is an AIMessage, use .content; otherwise pass the raw string\n",
    "result = parsing_llm.invoke({\"text\": response})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from json import JSONEncoder\n",
    "class MyEncoder(JSONEncoder):\n",
    "    def default(self, o):\n",
    "        return o.__dict__\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "result1 = MyEncoder().encode(result)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'patient_ID': 'MM082',\n",
       " 'disease_type': 'Multiple Myeloma',\n",
       " 'recomended_drug_name': 'Dexamethasone+Bortezomib+Pomalidomide_Proteasome Inhibitor regime'}"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "json.loads(result1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [],
   "source": [
    "llm_with_tools = llm.bind_tools([get_openfda_label])\n",
    "\n",
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"You are a helpful bioinformatics assistant. Use tools when needed.\"),\n",
    "    (\"human\", \"{question}\")\n",
    "])\n",
    "\n",
    "chain = prompt | llm_with_tools \n",
    "\n",
    "user_question = (\n",
    "    f\"\"\"Please tell me about each of recommended drugs: {json.loads(result1)['recomended_drug_name']} in the context of  {json.loads(result1)['disease_type']} \"\"\"\n",
    ")\n",
    "\n",
    "ai_msg = chain.invoke({\"question\": user_question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Tool calls: [{'name': 'get_openfda_label', 'args': {'ingredient': 'Dexamethasone'}, 'id': '0fd66b8b-7b67-4299-b7c0-cb713662bdcb', 'type': 'tool_call'}, {'name': 'get_openfda_label', 'args': {'ingredient': 'Bortezomib'}, 'id': '0ad19e2c-5e79-4e56-9995-438cbe76f4b5', 'type': 'tool_call'}, {'name': 'get_openfda_label', 'args': {'ingredient': 'Pomalidomide'}, 'id': 'c4268c65-f132-49ee-9dae-b06535d51d57', 'type': 'tool_call'}]\n"
     ]
    }
   ],
   "source": [
    "tool_calls = getattr(ai_msg, \"tool_calls\", [])\n",
    "print(\"Tool calls:\", tool_calls)\n",
    "# Execute each tool call by name with provided arguments\n",
    "tools_by_name = {enrichr_query.name: enrichr_query}\n",
    "\n",
    "tool_results = []\n",
    "for call in tool_calls:\n",
    "    name = call[\"name\"]\n",
    "    args = call.get(\"args\", {})\n",
    "    if name in tools_by_name:\n",
    "        result = tools_by_name[name].invoke(args)\n",
    "        tool_resul"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "This regimen, combining Dexamethasone, Bortezomib, and Pomalidomide, is a powerful triple-drug approach often used in the treatment of Multiple Myeloma, particularly in the relapsed or refractory setting. Each drug targets myeloma cells through distinct mechanisms, leading to a synergistic effect.\n",
      "\n",
      "Here's a breakdown of each recommended drug:\n",
      "\n",
      "### 1. Dexamethasone\n",
      "\n",
      "*   **Class:** Corticosteroid\n",
      "*   **Mechanism of Action:** Dexamethasone is a potent synthetic corticosteroid. In Multiple Myeloma, it acts in several ways:\n",
      "    *   **Direct Cytotoxicity:** It can directly induce apoptosis (programmed cell death) in myeloma cells.\n",
      "    *   **Immunosuppression/Anti-inflammatory:** It reduces inflammation and suppresses the immune system, which can be beneficial in managing certain symptoms or side effects.\n",
      "    *   **Synergistic Effect:** It enhances the anti-myeloma activity of many other drugs, including proteasome inhibitors (like Bortezomib) and immunomodulatory drugs (like Pomalidomide).\n",
      "*   **Role in Multiple Myeloma:** Dexamethasone is a cornerstone of almost all Multiple Myeloma treatment regimens, used both as a direct anti-myeloma agent and to potentiate the effects of other drugs.\n",
      "*   **Common Side Effects:** Hyperglycemia (high blood sugar), insomnia, mood changes (anxiety, irritability), fluid retention, increased appetite, indigestion, and increased risk of infection. Long-term use can lead to bone thinning (osteoporosis).\n",
      "\n",
      "### 2. Bortezomib\n",
      "\n",
      "*   **Class:** Proteasome Inhibitor\n",
      "*   **Mechanism of Action:** Bortezomib works by reversibly inhibiting the 26S proteasome, a protein complex responsible for degrading ubiquitinated proteins within cells. Myeloma cells are highly dependent on proteasome activity for survival due to their high protein turnover. By inhibiting the proteasome, Bortezomib leads to:\n",
      "    *   Accumulation of misfolded and ubiquitinated proteins, triggering cellular stress.\n",
      "    *   Disruption of cell cycle progression and signaling pathways.\n",
      "    *   Induction of apoptosis (programmed cell death) in cancer cells.\n",
      "*   **Role in Multiple Myeloma:** Bortezomib was the first-in-class proteasome inhibitor approved for Multiple Myeloma and is widely used in both newly diagnosed and relapsed/refractory settings.\n",
      "*   **Common Side Effects:** Peripheral neuropathy (numbness, tingling, pain in hands/feet), thrombocytopenia (low platelet count), neutropenia (low white blood cell count), fatigue, nausea, diarrhea, constipation, and rash.\n",
      "\n",
      "### 3. Pomalidomide\n",
      "\n",
      "*   **Class:** Immunomodulatory Drug (IMiD)\n",
      "*   **Mechanism of Action:** Pomalidomide is an IMiD that binds to the cereblon protein, a component of an E3 ubiquitin ligase complex. This binding leads to the degradation of specific target proteins (e.g., Aiolos and Ikaros) that are crucial for myeloma cell survival and proliferation. Its actions include:\n",
      "    *   **Direct Anti-Myeloma Activity:** Induces apoptosis and inhibits the growth of myeloma cells.\n",
      "    *   **Immunomodulation:** Enhances T-cell and natural killer (NK) cell-mediated immunity against myeloma cells.\n",
      "    *   **Anti-Angiogenic Activity:** Inhibits the formation of new blood vessels that support tumor growth.\n",
      "*   **Role in Multiple Myeloma:** Pomalidomide is primarily used in patients with relapsed or refractory Multiple Myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor, and have shown disease progression.\n",
      "*   **Common Side Effects:** Myelosuppression (neutropenia, thrombocytopenia, anemia), fatigue, constipation, diarrhea, nausea, and peripheral neuropathy. There is also a significant risk of venous thromboembolism (blood clots), requiring prophylactic anticoagulation.\n",
      "\n",
      "### The Dexamethasone+Bortezomib+Pomalidomide Regimen\n",
      "\n",
      "This combination regimen leverages the distinct mechanisms of action of each drug to achieve a more potent anti-myeloma effect.\n",
      "*   **Dexamethasone** enhances the efficacy of both Bortezomib and Pomalidomide, while also contributing its own cytotoxic effects.\n",
      "*   **Bortezomib** targets the proteasome, disrupting protein homeostasis in myeloma cells.\n",
      "*   **Pomalidomide** modulates the immune system and directly targets myeloma cells through cereblon binding.\n",
      "\n",
      "This triple combination is particularly effective in patients with relapsed/refractory Multiple Myeloma, especially those who have become resistant to or progressed on prior therapies that may have included other IMiDs (like lenalidomide) and proteasome inhibitors. The combination aims to overcome resistance and achieve deeper, more durable responses.\n"
     ]
    }
   ],
   "source": [
    "messages = []\n",
    "messages.extend(prompt.format_messages(question=user_question))\n",
    "messages.append(ai_msg)\n",
    "\n",
    "# Attach tool outputs so the model can read and summarize them\n",
    "for idx, tr in enumerate(tool_results):\n",
    "    # Convert complex objects to strings or JSON for reliability\n",
    "    payload_str = str(tr[\"output\"])  # or json.dumps(...)\n",
    "    messages.append(\n",
    "        ToolMessage(content=payload_str, name=tr[\"tool\"], tool_call_id=ai_msg.tool_calls[idx][\"id\"]) \n",
    "    )\n",
    "\n",
    "final_answer = llm.invoke(messages)\n",
    "print(final_answer.content)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Making sure of the added value of the tools"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"The combination of Dexamethasone, Bortezomib, and Pomalidomide (often abbreviated as **DVP** or **PVd**) is a highly effective regimen used in the treatment of Multiple Myeloma (MM), particularly in the relapsed/refractory setting, but also sometimes in newly diagnosed patients, especially those with high-risk features.\\n\\nThis regimen combines three distinct classes of drugs, each targeting different pathways crucial for myeloma cell survival and proliferation, leading to synergistic anti-myeloma activity.\\n\\nLet's break down each drug:\\n\\n---\\n\\n### 1. Dexamethasone (Corticosteroid)\\n\\n*   **Drug Class:** Corticosteroid\\n*   **Mechanism of Action (MoA) in Multiple Myeloma:**\\n    *   **Direct Cytotoxicity:** Dexamethasone induces apoptosis (programmed cell death) in myeloma cells by binding to glucocorticoid receptors, which then translocate to the nucleus and alter gene expression. This leads to the upregulation of pro-apoptotic genes and downregulation of anti-apoptotic genes.\\n    *   **Anti-inflammatory Effects:** While less direct in its anti-myeloma action, its anti-inflammatory properties can help manage symptoms associated with MM, such as bone pain and fatigue.\\n    *   **Immunosuppression:** Can modulate the immune microenvironment, though its primary role here is direct cytotoxicity and synergy.\\n    *   **Synergistic Effects:** Dexamethasone is known to enhance the efficacy of many other anti-myeloma agents, including proteasome inhibitors and IMiDs, by sensitizing myeloma cells to their effects.\\n*   **Role in DVP Regimen:** Dexamethasone serves as a foundational component, providing direct anti-myeloma activity and significantly enhancing the effectiveness of both Bortezomib and Pomalidomide. It's often given on the same days as the other agents to maximize synergy.\\n*   **Key Side Effects:** Insomnia, mood changes (anxiety, irritability), hyperglycemia (high blood sugar), fluid retention, increased appetite, indigestion, increased risk of infection, and long-term effects like bone density loss.\\n\\n---\\n\\n### 2. Bortezomib (Proteasome Inhibitor)\\n\\n*   **Drug Class:** Proteasome Inhibitor (PI)\\n*   **Mechanism of Action (MoA) in Multiple Myeloma:**\\n    *   **Proteasome Inhibition:** Bortezomib is a reversible inhibitor of the 26S proteasome, a multi-enzyme complex responsible for degrading ubiquitinated proteins within the cell. Myeloma cells are particularly vulnerable to proteasome inhibition because they produce large amounts of abnormal proteins (e.g., monoclonal immunoglobulin) and rely heavily on the proteasome to maintain protein homeostasis.\\n    *   **Accumulation of Proteins:** By inhibiting the proteasome, Bortezomib causes an accumulation of misfolded and ubiquitinated proteins within the myeloma cell.\\n    *   **Endoplasmic Reticulum (ER) Stress:** This protein accumulation leads to severe ER stress, triggering the unfolded protein response (UPR) and ultimately inducing apoptosis.\\n    *   **NF-κB Inhibition:** Bortezomib also inhibits the NF-κB signaling pathway, which is constitutively active in myeloma cells and promotes their survival and proliferation.\\n    *   **Other Effects:** It can also affect cell cycle progression, angiogenesis, and cell adhesion.\\n*   **Role in DVP Regimen:** Bortezomib is a core anti-myeloma agent in this regimen, directly targeting a critical pathway for myeloma cell survival. Its distinct mechanism of action complements Pomalidomide and Dexamethasone.\\n*   **Key Side Effects:** Peripheral neuropathy (a significant concern, often dose-limiting), thrombocytopenia (low platelet count), fatigue, gastrointestinal issues (nausea, diarrhea, constipation), and a risk of herpes zoster reactivation (prophylaxis with antiviral medication is typically recommended).\\n\\n---\\n\\n### 3. Pomalidomide (Immunomodulatory Drug - IMiD)\\n\\n*   **Drug Class:** Immunomodulatory Drug (IMiD), a second-generation thalidomide analog.\\n*   **Mechanism of Action (MoA) in Multiple Myeloma:** Pomalidomide exerts its effects through multiple pathways, primarily by binding to the protein **cereblon (CRBN)**, a component of an E3 ubiquitin ligase complex. This binding leads to:\\n    *   **Degradation of Lymphoid Transcription Factors:** Pomalidomide binding to CRBN leads to the ubiquitination and subsequent proteasomal degradation of specific lymphoid transcription factors, **Aiolos** and **Ikaros**. These factors are crucial for myeloma cell survival and proliferation. Their degradation results in:\\n        *   **Direct Anti-Myeloma Activity:** Induction of apoptosis and cell cycle arrest in myeloma cells.\\n        *   **Inhibition of Myeloma Cell Adhesion:** Reduces interaction with the bone marrow microenvironment.\\n    *   **Immunomodulatory Effects:**\\n        *   Enhances T-cell and Natural Killer (NK) cell activity, leading to increased anti-tumor immunity.\\n        *   Inhibits regulatory T-cells (Tregs) and myeloid-derived suppressor cells (MDSCs), which normally suppress immune responses.\\n        *   Increases the production of anti-inflammatory cytokines (e.g., IL-2, IFN-γ) and decreases pro-inflammatory cytokines (e.g., TNF-α, IL-6).\\n    *   **Anti-angiogenic Effects:** Inhibits the formation of new blood vessels that support tumor growth.\\n*   **Role in DVP Regimen:** Pomalidomide adds a third powerful anti-myeloma agent with a distinct mechanism of action. Its direct cytotoxic, immunomodulatory, and anti-angiogenic effects provide a comprehensive attack on myeloma cells, often overcoming resistance to other therapies. It works synergistically with both Bortezomib and Dexamethasone.\\n*   **Key Side Effects:** Myelosuppression (primarily neutropenia – low white blood cell count, and thrombocytopenia), fatigue, deep vein thrombosis (DVT) and pulmonary embolism (PE) – requiring thromboprophylaxis (e.g., aspirin or anticoagulants), peripheral neuropathy (less common and severe than with thalidomide or bortezomib), and rash.\\n\\n---\\n\\n### Synergy of the DVP Combination\\n\\nThe power of the DVP regimen lies in the **synergy** between these three drugs:\\n\\n*   **Multi-Targeted Approach:** Each drug targets different, yet interconnected, pathways essential for myeloma cell survival and proliferation. This multi-pronged attack makes it harder for myeloma cells to develop resistance.\\n*   **Enhanced Apoptosis:** Dexamethasone sensitizes myeloma cells to the apoptotic effects of both Bortezomib and Pomalidomide.\\n*   **Complementary Mechanisms:** Bortezomib induces ER stress and inhibits NF-κB, while Pomalidomide degrades key transcription factors and modulates the immune system. These distinct mechanisms amplify the overall anti-myeloma effect.\\n*   **Overcoming Resistance:** This combination can be effective in patients who have become refractory to single agents or simpler combinations.\\n\\nIn summary, Dexamethasone + Bortezomib + Pomalidomide is a highly effective and commonly used regimen in Multiple Myeloma, leveraging the distinct yet complementary mechanisms of a corticosteroid, a proteasome inhibitor, and an immunomodulatory drug to achieve deep and durable responses.\""
      ]
     },
     "execution_count": 52,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\n",
    "prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"You are a helpful bioinformatics assistant..\"),\n",
    "    (\"human\", \"{text}\")\n",
    "])\n",
    "\n",
    "chain = prompt | llm | StrOutputParser()\n",
    "\n",
    "chain.invoke({\"text\": user_question})\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Functional Analysis of SHAP Features by Predicted Drug Response Class"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## SHAP values interpretation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/var/folders/wb/psbn1mfd7pl4ypjlvsjv81z00000gq/T/ipykernel_67662/166473241.py:90: LangChainDeprecationWarning: The method `BaseTool.__call__` was deprecated in langchain-core 0.1.47 and will be removed in 1.0. Use :meth:`~invoke` instead.\n",
      "  enrichr_query({\"gene_list\": list(set(feats[\"positive\"]))}) if feats[\"positive\"] else None\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "### Drugs Predicted as no_effect\n",
      "The positive SHAP features, which support a \"no_effect\" prediction, are primarily associated with the regulation of immune responses, specifically involving T cell proliferation and activation (genes like IL15, CD3E, ICAM3). Other notable functions include cell-cell adhesion mediated by integrins (CD3E, ADA), posttranscriptional regulation of gene expression (NUDT21, RBM4B), and protein-containing complex assembly (CUL1, SNX9, CD3E). There's also an indication of substantia nigra development (GLUD1, CNP) and cellular response to indole-3-methanol (CTNNA1).\n",
      "\n",
      "Conversely, the negative SHAP features, which argue against a \"no_effect\" prediction, are strongly linked to various aspects of immune response, particularly neutrophil-mediated immunity, degranulation, and activation (genes such as CTSZ, HLA-B, HP, SRP14, SERPINB6). These features also highlight the positive regulation of T cell and leukocyte-mediated cytotoxicity and immunity (HLA-B, HLA-DRA), as well as the interferon-gamma-mediated signaling pathway (HLA-B, HLA-DRA). Additionally, there are terms related to the regulation of actin filament-based processes (ARHGAP18, RHOC) and neuron death (GPNMB, CTSZ).\n",
      "\n",
      "### Drugs Predicted as positive_effect\n",
      "The positive SHAP features, supporting a \"positive_effect,\" are primarily associated with **gene expression regulation**, particularly through **miRNA-mediated mechanisms**. Key processes include negative regulation of gene expression, mRNA cleavage, miRNA loading onto RISC, and regulation of miRNA-mediated inhibition of translation, with genes like AGO1, EIF4E2, and YY1 being central. Other notable pathways include **lipoxin metabolic and biosynthetic processes** (ALOX5AP), **establishment of mitochondrion localization** (RHOT2), **death-inducing signaling complex assembly** (TRADD), and **RNA secondary structure unwinding** (AGO1).\n",
      "\n",
      "Conversely, the negative SHAP features, acting against a \"positive_effect,\" are linked to **pyrimidine nucleobase and ribonucleotide metabolic and biosynthetic processes** (DHODH). They also involve **immune response** pathways such as peptide transport, antigen processing and presentation via MHC class I (TAP2), and regulation/negative regulation of chemokine-mediated signaling pathways (RNF113A). Additionally, these features are associated with the **positive regulation of vascular endothelial growth factor signaling pathway** (MYO1C) and **vesicle fusion with the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) membrane** (TAP2).\n"
     ]
    }
   ],
   "source": [
    "# notebook.ipynb\n",
    "import json\n",
    "\n",
    "# --- Setup LLM + chain ---\n",
    "llm_with_tools = get_llm_with_tools()\n",
    "chain = get_prompt_chain(llm_with_tools)\n",
    "\n",
    "# --- Analyze patient ---\n",
    "results, summaries = analyze_patient(patient_json, patient_id, chain)\n",
    "\n",
    "# --- Show results ---\n",
    "for cls, summary in summaries.items():\n",
    "    print(f\"\\n### Drugs Predicted as {cls}\")\n",
    "    print(summary)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Patient Knowledge Graph Integration"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "patient_id = \"MM082\"\n",
    "# Path to your JSON file (e.g., patient PKG or classification output)\n",
    "KG_json_path = f\"{global_path}/patient_graphs_json/{patient_id}_KG.json\"\n",
    "\n",
    "with open(KG_json_path, \"r\") as f:\n",
    "    patient_KG_json = json.load(f)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain.schema import StrOutputParser\n",
    "\n",
    "patient_id = \"MM082\"\n",
    "KG_json_path = f\"{global_path}/patient_graphs_json/{patient_id}_KG.json\"\n",
    "\n",
    "with open(KG_json_path, \"r\") as f:\n",
    "    patient_KG_json = json.load(f)\n",
    "\n",
    "KG_prompt = ChatPromptTemplate.from_messages([\n",
    "    (\n",
    "        \"system\",\n",
    "        \"\"\"You are a helpful biomedical-AI assistant that interprets patient knowledge graphs for clinicians.\n",
    "\n",
    "TASK:\n",
    "Given the PKG and the training links, for patient {patient_id}:\n",
    "\n",
    "1. For each regimen (drug/treatment), list the training patients whose **Training_True_Class** matches {patient_id}’s **Predicted_Class** (“same effect”).\n",
    "2. Summarize clinically relevant metadata for those matched patients:\n",
    "   - Age\n",
    "   - Sex\n",
    "   - Treatment stage and prior lines\n",
    "   - Isotype and light chain\n",
    "   - Phenogroup\n",
    "   - sFLC range\n",
    "   - Key cytogenetics (del17p, t(11;14), t(4;14), 1q gain, hyperdiploidy, hypodiploidy)\n",
    "\n",
    "FORMAT:\n",
    "- Organize the output by regimen.\n",
    "- Keep the summaries concise and geared toward treatment decisions.\n",
    "\"\"\"\n",
    "    ),\n",
    "    (\n",
    "        \"user\",\n",
    "        \"\"\"Here is the patient KG JSON:\n",
    "{JSON_input}\"\"\"\n",
    "    )\n",
    "])\n",
    "\n",
    "# Build chain\n",
    "chain = KG_prompt | llm | StrOutputParser()\n",
    "\n",
    "# Invoke chain, filling in the placeholders\n",
    "KG_response = chain.invoke({\n",
    "    \"patient_id\": patient_id,\n",
    "    \"JSON_input\": json.dumps(patient_KG_json)\n",
    "})\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "\"Here is the summary of training patients whose treatment outcomes match MM082's predicted class for each regimen:\\n\\n**Regimen: Lenalidomide_Corticosteroid + IMID** (MM082 Predicted Class: no_effect)\\n- **Patient MM021**\\n  - Age: 71, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: 1q gain: Present\\n- **Patient MM023**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 712.5 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM025**\\n  - Age: 65, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 53 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM026**\\n  - Age: 59, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 533 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM027**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM028**\\n  - Age: 62, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group2\\n  - sFLC range: 711 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM042**\\n  - Age: 79, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 30 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM044**\\n  - Age: 63, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 32.1 mg/L\\n  - Key Cytogenetics: del17p: Present\\n- **Patient MM046**\\n  - Age: 79, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group3\\n  - sFLC range: 3633.3 mg/L\\n  - Key Cytogenetics: t(11;14): Present\\n- **Patient MM047**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 168.7 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM048**\\n  - Age: 60, Sex: m\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 28 mg/L\\n  - Key Cytogenetics: t(11;14): Present\\n- **Patient MM049**\\n  - Age: 43, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group2\\n  - sFLC range: 170 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM051**\\n  - Age: 80, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 853.7 mg/L\\n  - Key Cytogenetics: 1q gain: Present\\n- **Patient MM053**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 118 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM058**\\n  - Age: 55, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM061**\\n  - Age: 74, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 1258.2 mg/L\\n  - Key Cytogenetics: t(11;14): Present\\n- **Patient MM062**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 27 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM065**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group1\\n  - sFLC range: 83 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM069**\\n  - Age: 48, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 15 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM075**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM077**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group2\\n  - sFLC range: 332 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM079**\\n  - Age: 66, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 4 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM081**\\n  - Age: 54, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa/IgA-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM084**\\n  - Age: 75, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 940 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM092**\\n  - Age: 81, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 2\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM094**\\n  - Age: 68, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 2246 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n\\n**Regimen: Prednisone_Corticosteroid** (MM082 Predicted Class: no_effect)\\n- **Patient MM023**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 712.5 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM025**\\n  - Age: 65, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 53 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM026**\\n  - Age: 59, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 533 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM027**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM036**\\n  - Age: 51, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 7 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM037**\\n  - Age: 40, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 68.4 mg/L\\n  - Key Cytogenetics: del17p: Present, Hyperdiploidy: Present\\n- **Patient MM044**\\n  - Age: 63, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 32.1 mg/L\\n  - Key Cytogenetics: del17p: Present\\n- **Patient MM047**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 168.7 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM049**\\n  - Age: 43, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group2\\n  - sFLC range: 170 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM051**\\n  - Age: 80, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 853.7 mg/L\\n  - Key Cytogenetics: 1q gain: Present\\n- **Patient MM053**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 118 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM059**\\n  - Age: 64, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 2\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 11 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM061**\\n  - Age: 74, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 1258.2 mg/L\\n  - Key Cytogenetics: t(11;14): Present\\n- **Patient MM062**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 27 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM065**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group1\\n  - sFLC range: 83 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM067**\\n  - Age: 69, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 6006 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM070**\\n  - Age: 68, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 194 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM072**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group2\\n  - sFLC range: 178.4 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM075**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM077**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group2\\n  - sFLC range: 332 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM078**\\n  - Age: 44, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group2\\n  - sFLC range: 1 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM079**\\n  - Age: 66, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 4 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM081**\\n  - Age: 54, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa/IgA-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM084**\\n  - Age: 75, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 940 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM089**\\n  - Age: 69, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 3.4 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM092**\\n  - Age: 81, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 2\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM094**\\n  - Age: 68, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 2246 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n\\n**Regimen: Thalidomide_Corticosteroid + IMID** (MM082 Predicted Class: no_effect)\\n- **Patient MM023**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 712.5 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM025**\\n  - Age: 65, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 53 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM026**\\n  - Age: 59, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 533 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM027**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM028**\\n  - Age: 62, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group2\\n  - sFLC range: 711 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM036**\\n  - Age: 51, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 7 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM039**\\n  - Age: 69, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 1266 mg/L\\n  - Key Cytogenetics: del17p: Present, Hyperdiploidy: Present\\n- **Patient MM042**\\n  - Age: 79, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 30 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM044**\\n  - Age: 63, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 32.1 mg/L\\n  - Key Cytogenetics: del17p: Present\\n- **Patient MM047**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 168.7 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM048**\\n  - Age: 60, Sex: m\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 28 mg/L\\n  - Key Cytogenetics: t(11;14): Present\\n- **Patient MM051**\\n  - Age: 80, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 853.7 mg/L\\n  - Key Cytogenetics: 1q gain: Present\\n- **Patient MM053**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 118 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM058**\\n  - Age: 55, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM061**\\n  - Age: 74, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 1258.2 mg/L\\n  - Key Cytogenetics: t(11;14): Present\\n- **Patient MM065**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group1\\n  - sFLC range: 83 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM067**\\n  - Age: 69, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 6006 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM070**\\n  - Age: 68, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 194 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM075**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM077**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group2\\n  - sFLC range: 332 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM079**\\n  - Age: 66, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 4 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM081**\\n  - Age: 54, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa/IgA-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM084**\\n  - Age: 75, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 940 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM089**\\n  - Age: 69, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 3.4 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM094**\\n  - Age: 68, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 2246 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n\\n**Regimen: Dexamethasone+Bortezomib+Pomalidomide_Proteasome Inhibitor regime** (MM082 Predicted Class: positive_effect)\\n- **Patient MM021**\\n  - Age: 71, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: 1q gain: Present\\n- **Patient MM023**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 712.5 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM026**\\n  - Age: 59, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: 533 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM027**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: LC-Lambda\\n  - Phenogroup: Group1\\n  - sFLC range: None reported as present mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM028**\\n  - Age: 62, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Lambda\\n  - Phenogroup: Group2\\n  - sFLC range: 711 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM033**\\n  - Age: 79, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 501 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM042**\\n  - Age: 79, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 3+\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 30 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM051**\\n  - Age: 80, Sex: m\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 853.7 mg/L\\n  - Key Cytogenetics: 1q gain: Present\\n- **Patient MM053**\\n  - Age: 69, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: LC-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 118 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM058**\\n  - Age: 55, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM059**\\n  - Age: 64, Sex: f\\n  - Treatment Stage: treatment control, Prior Lines: 2\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 11 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM062**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group2\\n  - sFLC range: 27 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM067**\\n  - Age: 69, Sex: f\\n  - Treatment Stage: untreated, Prior Lines: 0\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 6006 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM069**\\n  - Age: 48, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 15 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM070**\\n  - Age: 68, Sex: f\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 194 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM072**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group2\\n  - sFLC range: 178.4 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM075**\\n  - Age: 64, Sex: m\\n  - Treatment Stage: treatment control, Prior Lines: 1\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 14 mg/L\\n  - Key Cytogenetics: Hyperdiploidy: Present\\n- **Patient MM077**\\n  - Age: 63, Sex: f\\n  - Treatment Stage: control after allo-TPL, Prior Lines: 1\\n  - Isotype/Light Chain: N/A\\n  - Phenogroup: Group2\\n  - sFLC range: 332 mg/L\\n  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\\n- **Patient MM084**\\n  - Age: 75, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 1\\n  - Isotype/Light Chain: IgA-Kappa\\n  - Phenogroup: Group1\\n  - sFLC range: 940 mg/L\\n  - Key Cytogenetics: None reported as present\\n- **Patient MM106**\\n  - Age: 53, Sex: m\\n  - Treatment Stage: relapse/progress, Prior Lines: 2\\n  - Isotype/Light Chain: IgG-Kappa\\n  - Phenogroup: Group3\\n  - sFLC range: 7110.1 mg/L\\n  - Key Cytogenetics: None reported as present\""
      ]
     },
     "execution_count": 19,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "KG_response"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "def print_regimen_summary(summary_text: str):\n",
    "    \"\"\"\n",
    "    Takes the structured markdown-style text (from LLM) and prints \n",
    "    it with clear section separators for readability.\n",
    "    \"\"\"\n",
    "    regimens = summary_text.split(\"**Regimen:\")\n",
    "    for block in regimens:\n",
    "        block = block.strip()\n",
    "        if not block:\n",
    "            continue\n",
    "        print(\"=\"*80)\n",
    "        print(\"REGIMEN:\", block.split(\"**\")[0].strip())  \n",
    "        print(\"=\"*80)\n",
    "        # Print the rest\n",
    "        lines = block.split(\"\\n\")\n",
    "        for line in lines[1:]:\n",
    "            print(line)\n",
    "        print(\"\\n\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================================================================\n",
      "REGIMEN: Here is the summary of training patients whose treatment outcomes match MM082's predicted class for each regimen:\n",
      "================================================================================\n",
      "\n",
      "\n",
      "================================================================================\n",
      "REGIMEN: Lenalidomide_Corticosteroid + IMID\n",
      "================================================================================\n",
      "- **Patient MM021**\n",
      "  - Age: 71, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: 1q gain: Present\n",
      "- **Patient MM023**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 712.5 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM025**\n",
      "  - Age: 65, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 53 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM026**\n",
      "  - Age: 59, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 533 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM027**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM028**\n",
      "  - Age: 62, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 711 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM042**\n",
      "  - Age: 79, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 30 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM044**\n",
      "  - Age: 63, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 32.1 mg/L\n",
      "  - Key Cytogenetics: del17p: Present\n",
      "- **Patient MM046**\n",
      "  - Age: 79, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 3633.3 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present\n",
      "- **Patient MM047**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 168.7 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM048**\n",
      "  - Age: 60, Sex: m\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 28 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present\n",
      "- **Patient MM049**\n",
      "  - Age: 43, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 170 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM051**\n",
      "  - Age: 80, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 853.7 mg/L\n",
      "  - Key Cytogenetics: 1q gain: Present\n",
      "- **Patient MM053**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 118 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM058**\n",
      "  - Age: 55, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM061**\n",
      "  - Age: 74, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 1258.2 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present\n",
      "- **Patient MM062**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 27 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM065**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 83 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM069**\n",
      "  - Age: 48, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 15 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM075**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM077**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 332 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM079**\n",
      "  - Age: 66, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 4 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM081**\n",
      "  - Age: 54, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa/IgA-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM084**\n",
      "  - Age: 75, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 940 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM092**\n",
      "  - Age: 81, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 2\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM094**\n",
      "  - Age: 68, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 2246 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "\n",
      "\n",
      "================================================================================\n",
      "REGIMEN: Prednisone_Corticosteroid\n",
      "================================================================================\n",
      "- **Patient MM023**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 712.5 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM025**\n",
      "  - Age: 65, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 53 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM026**\n",
      "  - Age: 59, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 533 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM027**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM036**\n",
      "  - Age: 51, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 7 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM037**\n",
      "  - Age: 40, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 68.4 mg/L\n",
      "  - Key Cytogenetics: del17p: Present, Hyperdiploidy: Present\n",
      "- **Patient MM044**\n",
      "  - Age: 63, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 32.1 mg/L\n",
      "  - Key Cytogenetics: del17p: Present\n",
      "- **Patient MM047**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 168.7 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM049**\n",
      "  - Age: 43, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 170 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM051**\n",
      "  - Age: 80, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 853.7 mg/L\n",
      "  - Key Cytogenetics: 1q gain: Present\n",
      "- **Patient MM053**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 118 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM059**\n",
      "  - Age: 64, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 2\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 11 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM061**\n",
      "  - Age: 74, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 1258.2 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present\n",
      "- **Patient MM062**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 27 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM065**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 83 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM067**\n",
      "  - Age: 69, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 6006 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM070**\n",
      "  - Age: 68, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 194 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM072**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 178.4 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM075**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM077**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 332 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM078**\n",
      "  - Age: 44, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 1 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM079**\n",
      "  - Age: 66, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 4 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM081**\n",
      "  - Age: 54, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa/IgA-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM084**\n",
      "  - Age: 75, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 940 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM089**\n",
      "  - Age: 69, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 3.4 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM092**\n",
      "  - Age: 81, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 2\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM094**\n",
      "  - Age: 68, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 2246 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "\n",
      "\n",
      "================================================================================\n",
      "REGIMEN: Thalidomide_Corticosteroid + IMID\n",
      "================================================================================\n",
      "- **Patient MM023**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 712.5 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM025**\n",
      "  - Age: 65, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 53 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM026**\n",
      "  - Age: 59, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 533 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM027**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM028**\n",
      "  - Age: 62, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 711 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM036**\n",
      "  - Age: 51, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 7 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM039**\n",
      "  - Age: 69, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 1266 mg/L\n",
      "  - Key Cytogenetics: del17p: Present, Hyperdiploidy: Present\n",
      "- **Patient MM042**\n",
      "  - Age: 79, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 30 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM044**\n",
      "  - Age: 63, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 32.1 mg/L\n",
      "  - Key Cytogenetics: del17p: Present\n",
      "- **Patient MM047**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 168.7 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM048**\n",
      "  - Age: 60, Sex: m\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 28 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present\n",
      "- **Patient MM051**\n",
      "  - Age: 80, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 853.7 mg/L\n",
      "  - Key Cytogenetics: 1q gain: Present\n",
      "- **Patient MM053**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 118 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM058**\n",
      "  - Age: 55, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM061**\n",
      "  - Age: 74, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 1258.2 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present\n",
      "- **Patient MM065**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 83 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM067**\n",
      "  - Age: 69, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 6006 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM070**\n",
      "  - Age: 68, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 194 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM075**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM077**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 332 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM079**\n",
      "  - Age: 66, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 4 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM081**\n",
      "  - Age: 54, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa/IgA-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM084**\n",
      "  - Age: 75, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 940 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM089**\n",
      "  - Age: 69, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 3.4 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM094**\n",
      "  - Age: 68, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 2246 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "\n",
      "\n",
      "================================================================================\n",
      "REGIMEN: Dexamethasone+Bortezomib+Pomalidomide_Proteasome Inhibitor regime\n",
      "================================================================================\n",
      "- **Patient MM021**\n",
      "  - Age: 71, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: 1q gain: Present\n",
      "- **Patient MM023**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 712.5 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM026**\n",
      "  - Age: 59, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 533 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM027**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: LC-Lambda\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: None reported as present mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM028**\n",
      "  - Age: 62, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Lambda\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 711 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM033**\n",
      "  - Age: 79, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 501 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM042**\n",
      "  - Age: 79, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 3+\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 30 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM051**\n",
      "  - Age: 80, Sex: m\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 853.7 mg/L\n",
      "  - Key Cytogenetics: 1q gain: Present\n",
      "- **Patient MM053**\n",
      "  - Age: 69, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: LC-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 118 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM058**\n",
      "  - Age: 55, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM059**\n",
      "  - Age: 64, Sex: f\n",
      "  - Treatment Stage: treatment control, Prior Lines: 2\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 11 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM062**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 27 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM067**\n",
      "  - Age: 69, Sex: f\n",
      "  - Treatment Stage: untreated, Prior Lines: 0\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 6006 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM069**\n",
      "  - Age: 48, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 15 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM070**\n",
      "  - Age: 68, Sex: f\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 194 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM072**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 178.4 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM075**\n",
      "  - Age: 64, Sex: m\n",
      "  - Treatment Stage: treatment control, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 14 mg/L\n",
      "  - Key Cytogenetics: Hyperdiploidy: Present\n",
      "- **Patient MM077**\n",
      "  - Age: 63, Sex: f\n",
      "  - Treatment Stage: control after allo-TPL, Prior Lines: 1\n",
      "  - Isotype/Light Chain: N/A\n",
      "  - Phenogroup: Group2\n",
      "  - sFLC range: 332 mg/L\n",
      "  - Key Cytogenetics: t(11;14): Present, 1q gain: Present, del17p: Present\n",
      "- **Patient MM084**\n",
      "  - Age: 75, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 1\n",
      "  - Isotype/Light Chain: IgA-Kappa\n",
      "  - Phenogroup: Group1\n",
      "  - sFLC range: 940 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "- **Patient MM106**\n",
      "  - Age: 53, Sex: m\n",
      "  - Treatment Stage: relapse/progress, Prior Lines: 2\n",
      "  - Isotype/Light Chain: IgG-Kappa\n",
      "  - Phenogroup: Group3\n",
      "  - sFLC range: 7110.1 mg/L\n",
      "  - Key Cytogenetics: None reported as present\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "summary_text = KG_response  \n",
    "print_regimen_summary(summary_text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
